A Phase 4 interventional study of low-dose epinephrine and tranexamic acid and Tranexamic Acid (TXA) treatment in Knee Arthroplasty, Total, Knee Arthritis, Osteoarthritis and Total Knee Anthroplasty, sponsored by King Abdullah International Medical Research Center. Recruiting at 1 site in Saudi Arabia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-28.
Sponsored by King Abdullah International Medical Research Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing Tranexamic Acid in Osteoarthritis — 3 open to participants now, 3 under way, 1 of them phase 3. Tranexamic Acid · Osteoarthritis.
Among the 15 studies testing Tranexamic Acid in Osteoarthritis, this one is the 12th largest by planned enrollment, is the only one that started in 2025, is one of 6 in phase 4, and was the 14th registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →3 of the 15 studies testing Tranexamic Acid in Osteoarthritis are open now, in 2 countries. Recruiting first, the newest first:
Western University, Canada
Hua Luo · Sites in China
Ages 18–80
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 6
First in 2012; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.
Median enrollment 149 across the 15 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 10 most frequent:
King Abdullah International Medical Research Center is the lead sponsor of 46 studies on the registry; 6 are open to participants now.
King Abdullah International Medical Research Center has 2 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
1 of the studies testing Tranexamic Acid in Osteoarthritis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07089251King Abdullah International Medical Research CenterThe Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery | 2027-06-24 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing Tranexamic Acid in Osteoarthritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this clinical trial is to evaluate the effect of administering low-dose epinephrine and tranexamic acid on perioperative blood loss, thromboembolic complications, and hospitalization duration in patients undergoing knee joint arthroplasty.
Also aim to evaluate the effect of administering low-dose epinephrine and tranexamic acid on perioperative thromboembolic complications, and hospitalization duration
Patients will be randomly divided into two groups: one receiving intravenous low-dose epinephrine and tranexamic acid, while the other will receive TXA alone as the control. Randomization to be done using a computer-generated table.
The study will be done a superiority clinical trial. with an estimated 24 hour blood loss of 300 ml, with standard deviation of 150 ml. a power of 80% and alpha 5%, an estimated sample size of 80 is needed to detect a difference.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The experimental group will receive both epinephrine and tranexamic acid
Drug: low-dose epinephrine and tranexamic acid
The comparator group will receive only tranexamic acid
Drug: Tranexamic Acid (TXA) treatment
Drug pages: EpinephrineStudies of EpinephrineEpinephrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Tranexamic AcidStudies of Tranexamic AcidTranexamic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
low-dose epinephrine and tranexamic acid
Tranexamic Acid
Perioperative blood loss
Calculated 24 h blood loss in mL, Hidden blood loss in mL, Hemoglobin levels in g/dL, Hematocrit levels as a percentage, Platelets count in cells/µL.
Time frame: Daily, till post-operative day 5
Thromboembolic complications
Time frame: Daily, till post-operative day 5
Hospitalization duration
Time frame: Daily, till post-operative day 5
Drug side effects (epinephrine + tranexamic acid)
Time frame: Daily, till post-operative day 5
Complications
VTE, SSI, UTI, AKI, Cardiac Arrhythmias, Stroke
Time frame: Daily, till post-operative day 5
Plan to share: Yes
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.
Of 54 non-industry phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 23 months is below that.
Counting every sponsor, half of 63 studies reached it within 28 months; a quarter within 11 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Epinephrine · Tranexamic Acid
King Abdullah International Medical Research Center